Emcure Pharmaceuticals Ltd
Emcure Pharmaceuticals Q1 FY26 earnings call: Revenue & Margins
Q1 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Emcure expects to achieve above-average growth over the next 5 years, aiming for about 2% more than the industry growth in India and other markets, including Europe and Canada. Emcure aims for above-average growth over the next 5 years, targeting about 2% higher growth than industry averages in all markets, including India, Europe, and Canada.
From Emcure Pharmaceuticals Ltd's Q1 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Emcure expects to achieve above-average growth over the next 5 years, aiming for about 2% more than the industry growth in India and other markets, including Europe and Canada.
- Domestic revenue grew 9.4% YoY in Q1 FY26, with 4% volume growth targeted for the full year.
- International markets showed strong momentum, growing 22% YoY, with emerging markets growing 42%.
- Canada operations are expected to sustain mid-teens growth.
- New initiatives in Derma and Consumer Wellness are projected to add 1%-2% incremental growth to the domestic business.
- Strategic product launches including Tenecteplase, Liposomal Amphotericin, and others are expected to drive significant ramp-up over the next 18-24 months.
2 more points from Emcure Pharmaceuticals Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Emcure Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Emcure expects annualized capex spending around INR 350 crores per year.
- Of this, approximately INR 150 crores is allocated to repair and maintenance.
- Around INR 200 crores is earmarked for capacity enhancements and product-specific capex.
- Most infrastructure required for the 4-5 year growth plan is already in place.
- The company continues to evaluate and pursue M&A, strategic alliances, and in-licensing deals, which may require capital allocation.
2 more points from Emcure Pharmaceuticals Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Emcure Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The transcript does not explicitly mention a specific current or expected order book or pending orders value.
- There are references to ongoing approvals and product launches such as Liposomal Amphotericin and Tenecteplase indicating future order potential.
- The company is optimistic about ramp-ups in markets like Europe, UK, US, and Emerging Markets over the next 12 months.
- Approval processes for products like Asparaginase and wet AMD are underway, which could add to future orders.
2 more points from Emcure Pharmaceuticals Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Emcure Pharmaceuticals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹2.5K Cr, net profit ₹244 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Emcure Pharmaceuticals Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- RPG LifeScience. (Q1 FY26)
168.9 crores vs Rs. Key concall takeaways from RPG Life Sciences Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
- SMS Pharma. (Q1 FY26)
Q1FY26 revenue from operations: ₹196.05 crore . Key concall takeaways from SMS Pharmaceuticals Ltd's Q1 FY26 earnings call — and how it ranks against sector…
- Morepen Labs. (Q1 FY26)
Crores)**: . Key concall takeaways from Morepen Laboratories Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
- Influx Health. (Q1 FY26)
FY25 revenue from operations: ₹104.9 crores, up 5% YoY from ₹99.9 crores in FY24 (Page 28 & 26). Key concall takeaways from Influx Healthtech Ltd's Q1 FY26…
Arthneeti Pro · Annual
Emcure Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Emcure Pharmaceuticals Ltd Q1 FY26 results?
Emcure expects to achieve above-average growth over the next 5 years, aiming for about 2% more than the industry growth in India and other markets, including Europe and Canada. Emcure aims for above-average growth over the next 5 years, targeting about 2% higher growth than industry averages in all markets, including India, Europe, and Canada.
What is Emcure Pharmaceuticals Ltd share price analysis?
Emcure Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 39.3 with a market cap of ₹37,158 Cr. Investors should review the full earnings analysis for detailed insights.
Is Emcure Pharmaceuticals Ltd planning capital expenditure?
Emcure expects annualized capex spending around INR 350 crores per year.
Keep Emcure Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.